The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SRC-homology 2 domain-containing phosphatase 2 (SHP2) in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD).
 
Rafael Rosell
No Relationships to Disclose
 
Masaoki Ito
No Relationships to Disclose
 
Jordi Codony-Servat
No Relationships to Disclose
 
Ana Giménez-Capitán
No Relationships to Disclose
 
Mireia Serra-Mitjans
No Relationships to Disclose
 
Francisco Pérez-Ochoa
No Relationships to Disclose
 
David Llige
No Relationships to Disclose
 
Imane Chaib
No Relationships to Disclose
 
Ramón Rami-Porta
No Relationships to Disclose
 
Carme Obiols
No Relationships to Disclose
 
Sergi Call
No Relationships to Disclose
 
José Belda-Sanchis
No Relationships to Disclose
 
Xavier Tarroch-Sarasa
No Relationships to Disclose
 
Niki Karachaliou
No Relationships to Disclose
 
Miguel Angel Molina Vila
No Relationships to Disclose
 
Morihito Okada
Speakers' Bureau - AstraZeneca; Chugai Pharma; Covidien; CSL Behring; Johnson & Johnson; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nihon Medi-Physics (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)